Trillium Therapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing some of their medical products and for their clinical analysis.
“Tumor-expressed CD200 can modulate anti-tumor responses in vitro and in vivo, and antibodies that block CD200 have been shown to promote anti-tumor immunity in animal models of cancer”
Trillium Therapeutics, Inc. is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc (TTI-621) program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic signals. [Source: Reuters]
Company Website: http://trilliumtherapeutics.com